论文部分内容阅读
目的:观察三参地萸汤对鼻咽癌放疗患者的增效减毒作用及对生活质量和转移的影响。方法:将120患者根据入院先后顺序按随机数字表法分为对照组和观察组。对照组行调强放射治疗,并配合静脉注射用还原型谷胱甘肽钠。观察组在对照组治疗的基础上加服三参地萸汤。两组疗程均至放疗结束后2周。记录急性放射反应情况;化疗前后采用欧洲癌症病人头颈专用量表(EORTC QLQ-H&N35)评价患者生存质量;进行治疗前后实体肿瘤大小评价;检测治疗前后EB病毒DNA(EBV-DNA),血管内皮生长因子(VEGF),骨型碱性磷酸酶(B-ALP)和基质金属蛋白酶-2(MMP-2)。结果:观察组总有效率为83.93%,高于对照组的67.27%(P<0.05);放疗结束时口腔黏膜、耳、唾液腺、咽、食管和喉的急性放射反应评分均低于对照组(P<0.01);QLQ-H&N35量表疼痛等7个症状评分均低于对照组(P<0.01),张口困难等9个单一症状评分均低于对照组(P<0.01);治疗后观察组血清EBV-DNA,B-ALP,MMP-2和VEGF水平均低于对照组(P<0.01)。结论:三参地萸汤辅助放射治疗NPC患者,具有减轻放射性损伤,改善或稳定患者生活质量,提高临床疗效和预防肿瘤转移的作用。
Objective: To observe the effect of San Shen Di Yu Tang on the synergic effect and attenuation of quality of life and metastasis of patients with nasopharyngeal carcinoma radiotherapy. Methods: 120 patients were randomly divided into control group and observation group according to the order of admission. Control group IMRT, and with intravenous injection of reduced glutathione sodium. Observation group in the control group based on the treatment plus serving three Senate Yu Tang. Two courses of treatment were to 2 weeks after the end of radiotherapy. The EORTC QLQ-H & N35 scale before and after chemotherapy was used to evaluate the quality of life of the patients. The size of the solid tumor before and after treatment was evaluated. The EBV-DNA and vascular endothelial growth (VEGF), bone alkaline phosphatase (B-ALP) and matrix metalloproteinase-2 (MMP-2). Results: The total effective rate in the observation group was 83.93%, which was higher than that in the control group (67.27%, P <0.05). The acute radiation reaction scores of oral mucosa, ear, salivary gland, pharynx, esophagus and larynx at the end of radiotherapy were lower than those of the control group (P <0.01). The scores of 7 symptoms such as QLQ-H & N35 were lower than those of the control group (P <0.01), 9 single symptoms such as difficulty of opening were lower than those of the control group (P <0.01) Serum EBV-DNA, B-ALP, MMP-2 and VEGF levels were lower than the control group (P <0.01). Conclusion: San Shen Tang decoction assisted radiotherapy in patients with NPC, with the reduction of radioactive injury, to improve or stabilize the quality of life of patients and improve the clinical efficacy and prevention of tumor metastasis.